Comparison between patients with biofilm-forming (BF) candidemia or non-biofilm-forming (NBF) candidemia in the matched cohort study.

NOTE.Results are shown as no. (%) or median with range. LOS, length of stay; ICU, intensive care unit; CBSI, Candida bloodstream infection; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; CVC, central venous catheter.
aDays of hospital stay prior to the onset of candidemia (or, for controls, total days in the hospital).
bNumber of hospital days from admission to the onset of candidemia (or, for controls, total days in the hospital).
cOther species includes Candida krusei (3 cases), Candida lusitaniae (2 cases), and Candida guilliermondii (1 case).
dAbsolute neutrophil count <500 cells/mm3.
eWithin 30 days prior to the onset of candidemia (or, for controls, at any point during hospitalization).
fTherapeutic failure at 72 h after starting antifungal therapy, as assessed by the persistence of infection or by the occurrence of death.